Nexletol comes as a tablet you swallow. It contains the active ingredient bempedoic acid. (An active ingredient is what makes a drug work.) Keep reading to learn about the common, mild ...

Shares in Esperion Therapeutics lost more than half of their value after it disclosed a dispute with Daiichi Sankyo on a $300 million milestone payment relating to cholesterol drug Nexletol.

JMP Securities analyst Jason Butler reiterated a Buy rating on Esperion (ESPR – Research Report) today and set a price target of $7.00.Invest ...

The Institute for Clinical and Economic Review (ICER) in the US published a draft report on Nexletol last month, which concluded that the drug was unlikely to be cost-effective at its current ...

Esperion (ESPR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from ...

JMP Securities reiterated its Market Outperform rating and $7.00 price target for Esperion Therapeutics (NASDAQ:ESPR) stock, ...

After hours: January 31 at 7:17:30 PM EST Loading Chart for DRUG ...

Harry Sumnall receives funding from public grant awarding bodies for alcohol and other drugs research, and fees from (international) not-for-profit organisations and government departments for ...

Sometimes you may receive a combination of therapies, or something else entirely. Oncology (cancer) drugs include a range of therapies and medications, such as chemotherapy drugs, targeted ...

Drugmakers raised the list prices on 575 name-brand drugs in just the first two days of the new year, according to drug price research firm 46brooklyn. Drugs for diabetes, HIV, cancer saw price ...

Drug discovery is the process through which potential new medicines are identified. It involves a wide range of scientific disciplines, including biology, chemistry and pharmacology. Large-scale ...

Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company with a market capitalization of $425 million and impressive revenue growth of 187% over the last twelve months, saw its Chief ...